See more : Hagiwara Electric Holdings Co., Ltd. (7467.T) Income Statement Analysis – Financial Results
Complete financial analysis of Allena Pharmaceuticals, Inc. (ALNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allena Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fision Corporation (FSSN) Income Statement Analysis – Financial Results
- ION Geophysical Corporation (IOGPQ) Income Statement Analysis – Financial Results
- Transcontinental Inc. (TCLCF) Income Statement Analysis – Financial Results
- China Pipe Group Limited (0380.HK) Income Statement Analysis – Financial Results
- Jindo.Co., Ltd. (088790.KS) Income Statement Analysis – Financial Results
Allena Pharmaceuticals, Inc. (ALNA)
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.38M | 20.38M | 37.24M | 26.38M | 15.52M | 20.10M | 11.54M |
| General & Administrative | 11.60M | 11.60M | 9.68M | 8.64M | 5.43M | 4.08M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 576.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 11.60M | 11.60M | 9.68M | 9.22M | 5.43M | 4.08M | 2.37M |
| Other Expenses | 0.00 | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Cost & Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 510.00K | -510.00K | 270.00K | 575.00K | -443.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 363.00K | 166.00K | 163.00K | 78.00K | 73.00K | 46.00K | 98.00K |
| EBITDA | -31.97M | -32.68M | -47.18M | -35.57M | -21.58M | -24.46M | -14.15M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.34M | -31.99M | -46.92M | -35.59M | -20.95M | -24.19M | -13.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -510.00K | -859.00K | 0.00 | -55.00K | -700.00K | -321.00K | -342.00K |
| Income Before Tax | -32.85M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 510.00K | -859.00K | -419.00K | -55.00K | -700.00K | -321.00K | -342.00K |
| Net Income | -33.36M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| EPS Diluted | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| Weighted Avg Shares Out | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
| Weighted Avg Shares Out (Dil) | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
Why Are Allena Pharma Shares Plunging Today
An independent data safety monitoring board (DSMB) has conducted the first of two planned Sample Size Reestimations (SSR1) of Phase 3 URIROX-2 Trial of Allena Pharmaceuticals Inc's (NASDAQ: ALNA) reloxaliase for enteric hyperoxaluria. Hyperoxaluria increases the risk of.
Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days
Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days
Allena Stock Is Surging In Premarket Today As It Explores Strategic, Financing Alternatives
Allena Pharmaceuticals Inc (NASDAQ: ALNA) posted data from the first cohort of the Phase 2 trial (Study 201) evaluating ALLN-346 for hyperuricemia and gout in advanced chronic kidney disease (CKD). The data demonstrated a statistically significant reduction in serum uric acid (sUA) from baseline...
Allena Pharmaceuticals Stock (ALNA): Why The Price Surged Today
The stock price of Allena Pharmaceuticals Inc (NASDAQ: ALNA) increased by over 55% pre-market today. This is why it happened.
Allena Pharmaceuticals, Inc. (ALNA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Allena Pharmaceuticals, Inc. (ALNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
After Plunging 19.7% in 4 Weeks, Here's Why the Trend Might Reverse for Allena Pharmaceuticals, Inc. (ALNA)
The heavy selling pressure might have exhausted for Allena Pharmaceuticals, Inc. (ALNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the...
Allena Pharmaceuticals (ALNA) Sees Hammer Chart Pattern: Time to Buy?
Allena Pharmaceuticals (ALNA) has been struggling lately, but the selling pressure may be coming to an end soon.
Hot Penny Stocks to Watch as AMC and GME Go to the Moon
Which penny stocks are you watching as GME stock and AMC stock shoot toward the moon? The post Hot Penny Stocks to Watch as AMC and GME Go to the Moon appeared first on Penny Stocks to Buy, Picks, News...
ALNA Stock: Why The Price Surged Today
The stock price of Allena Pharmaceuticals Inc (NASDAQ: ALNA) increased by over 20% during intraday trading today. This is why it happened.
Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress
NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases,...
Source: https://incomestatements.info
Category: Stock Reports